复宏汉霖今日盘中股价大幅上涨5.23%，引起了市场关注。
消息面上，招银国际发布研究报告，维持对复宏汉霖的“买入”评级，并将其目标价由97.75元微升至99.78元。报告指出，公司受益于稳健的产品销售增长，2025财年业绩表现强劲。同时，公司正积极扩大其全球生物类似药的市场版图，并建立新的国际合作伙伴关系，加速向创新生物制剂龙头企业转型。其产品线中HLX43、HLX22及serplulimab等具有竞争力的产品发展领先，预期2026年将出现多项临床及监管层面的积极催化因素。
复宏汉霖今日盘中股价大幅上涨5.23%，引起了市场关注。
消息面上，招银国际发布研究报告，维持对复宏汉霖的“买入”评级，并将其目标价由97.75元微升至99.78元。报告指出，公司受益于稳健的产品销售增长，2025财年业绩表现强劲。同时，公司正积极扩大其全球生物类似药的市场版图，并建立新的国际合作伙伴关系，加速向创新生物制剂龙头企业转型。其产品线中HLX43、HLX22及serplulimab等具有竞争力的产品发展领先，预期2026年将出现多项临床及监管层面的积极催化因素。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.